Publication:
Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study

Simple item page
dc.contributor.authorsYalcin, Suayib; Uslu, Ruchan; Dane, Faysal; Yilmaz, Ugur; Zengin, Nurullah; Buyukunal, Evin; Buyukberber, Suleyman; Camci, Celalettin; Sencan, Orhan; Kilickap, Saadettin; Ozdener, Fatih; Cevik, Duygu
dc.date.accessioned2022-03-12T16:14:01Z
dc.date.accessioned2026-01-11T10:28:16Z
dc.date.available2022-03-12T16:14:01Z
dc.date.issued2012
dc.identifier.doidoiWOS:000318009804818
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/225192
dc.identifier.wosWOS:000318009804818
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleBevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.issue15
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume30

Files

Collections

Araştırma Çıktıları